The predictive value of serum YKL-40 and GDF-15 levels for clinical outcomes in patients with Parkinson disease
10.3760/cma.j.cn371468-20250217-00057
- VernacularTitle:帕金森病患者血清YKL-40、GDF-15对临床转归的预测价值
- Author:
Lin ZHANG
1
;
Shuxin CHENG
;
Shixun GUO
;
Chunyin LIU
;
Bingqian MA
;
Jingjing REN
;
Jingfang JI
Author Information
1. 新乡市中心医院康复医学科，新乡 453000
- Publication Type:Journal Article
- Keywords:
Parkinson disease;
Human cartilage glycoprotein 39;
Growth differentiation factor 15;
Clinical outcomes;
Specificity;
Sensitivity
- From:
Chinese Journal of Behavioral Medicine and Brain Science
2025;34(7):613-617
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the predictive value of human cartilage glycoprotein 39 (YKL-40) and growth differentiation factor 15 (GDF-15) for clinical outcomes of patients with Parkinson disease (PD).Methods:A total of 109 patients with PD admitted to Xinxiang Central Hospital from February 2021 to February 2023 were selected and treated with regular anti-PD medications for 4 weeks, with dosage appropriately adjusted according to clinical status and individual response.Clinical outcomes were evaluated after 2 months of treatment, and the predictive value of serum YKL-40 and GDF-15 at admission for clinical outcomes was analyzed.Data were analyzed by independent sample t-test, χ2 test and Logistic regression using SPSS 26.0. Results:PD patients with poor outcomes exhibited higher serum levels of YKL-40((3.18±0.67)mg/L, (2.34±0.41)mg/L) and GDF-15((457.82±142.83)pg/mL, (282.95±105.96)pg/mL) than those with good outcomes, and the differences were statistically significant ( t=8.082, 7.349, both P<0.05).Logistic regression analysis showed that elevated serum levels of YKL-40( B=0.664, OR=1.943, 95% CI=1.237-3.052) and GDF-15( B=0.185, OR=1.787, 95% CI=1.145-2.789) both influenced the clinical outcomes of PD patients(both P<0.05).Serum YKL-40 combined with GDF-15 demonstrated a predictive sensitivity of 87.23%, specificity of 90.32%, and AUC of 0.927(95% CI=0.861-0.968) for clinical outcomes in PD patients.The AUC was significantly higher than that achieved by either indicator alone (YKL-40: AUC (95% CI)=0.722 (0.628-0.804); GDF-15: AUC (95% CI)=0.797 (0.709-0.868)). Conclusion:The elevated levels of YKL-40 and GDF-15 in PD patients are associated with clinical outcomes, which may be the potential markers for predicting clinical outcomes of patients with PD.
